Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18994385 | 0.86 | NOS1 (0.31) | NOS1HRH1KCNH2 | |
| SCHEMBL6440593 | 0.81 | NOS1 (0.34) | NOS1HRH1KCNH2 | |
| SCHEMBL12863924 | 0.80 | NOS1 (0.36) | NOS1HRH1KCNH2 | |
| SCHEMBL5713342 | 0.79 | NOS1 (0.34) | NOS1HRH1KCNH2 | |
| SCHEMBL174399 | 0.79 | — | — | |
| SCHEMBL6022879 | 0.77 | — | — | |
| Bromide SCHEMBL27878723 | 0.77 | — | — | |
| SCHEMBL18310667 | 0.76 | NOS1 (0.31) | NOS1HRH1KCNH2 | |
| SCHEMBL21606214 | 0.76 | NOS1 (0.31) | NOS1HRH1KCNH2 | |
| SCHEMBL11493460 | 0.76 | NOS1 (0.34) | NOS1HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840529-B2 | Substituted pyrimidines as LRKK2 inhibitors | DENALI THERAPEUTICS INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11767341-B2 | Lincosamide antibiotics and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767341-B2 | Lincosamide antibiotics and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-09-26 | — | — | US | disclosed |
| US-11566039-B2 | Lincosamide antibiotics and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220073554-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-10 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210087215-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-03-25 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190224188-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9815853-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-8501786-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767341-B2 | Lincosamide antibiotics and uses thereof | LNPEP, LCLAT1, NPEPPS | NOS1 1833/4885HRH1 2753/4885KCNH2 3261/4885 |
| US-11840529-B2 | Substituted pyrimidines as LRKK2 inhibitors | LRRK2, DTYMK, LMTK2 | NOS1 4828/4885HRH1 979/4885KCNH2 3942/4885 |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | NOS1 3596/4885HRH1 1292/4885KCNH2 559/4885 |
| US-20190224188-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HDGF, HAVCR2 | NOS1 2533/4885HRH1 2028/4885KCNH2 4374/4885 |
| US-11566039-B2 | Lincosamide antibiotics and uses thereof | NPEPPS, ASNS, LNPEP | NOS1 3142/4885HRH1 3460/4885KCNH2 3234/4885 |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | NOS1 1088/4885HRH1 207/4885KCNH2 565/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | NOS1 825/4885HRH1 316/4885KCNH2 409/4885 |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | HCCS, HDGF, HAVCR2 | NOS1 2533/4885HRH1 2028/4885KCNH2 4374/4885 |
| US-20100120740-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, AOC1 | NOS1 371/4885HRH1 827/4885KCNH2 2504/4885 |
| US-20110034434-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, AOC1 | NOS1 371/4885HRH1 827/4885KCNH2 2504/4885 |
| US-20210087215-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | NPEPPS, ASNS, LNPEP | NOS1 3142/4885HRH1 3460/4885KCNH2 3234/4885 |
| US-20220073554-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | LNPEP, LCLAT1, NPEPPS | NOS1 1867/4885HRH1 3034/4885KCNH2 3207/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | NOS1 1718/4885HRH1 1920/4885KCNH2 4492/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | NOS1 1718/4885HRH1 1920/4885KCNH2 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.